KBC Securities - MAAT PHARMA SA (MAAT) MaaT Pharma - Doses first patient in phase 2b MaaT033 trial in allo-HSCT Doses first patient in phase 2b MaaT033 trial in allo-HSCT

Report

KBC Securities

Jacob Mekhael

MaaT Pharma - Doses first patient in phase 2b MaaT033 trial in allo-HSCT Doses first patient in phase 2b MaaT033 trial in allo-HSCT

MaaT announced that the first patient has been treated in the phase 2b (PHOEBUS) trial of MaaT033 (microbiome therapy, oral formulation) in patients with blood cancer receiving allo-HSCT. This comes in line with the company's timeline guidance demonstrating progress on the next growth leg for MaaT. We look forward to the first readout expected in late 2026, while the next trigger for the stock remains the phase 3 topline data for MaaT013 in aGvHD expected in mid-2024. We reiterate our BUY rating and €15 TPHere

06/11/2023 1 EN

Underlying

MAAT PHARMA SA

See profile

FR0012634822 Euronext Paris France

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

KBC Securities

Morning Notes : OPTI BB, SOF BB, WDP BB, MAAT FP

: OPTI BB, SOF BB, WDP BB, MAAT FP

January 21, 2026 January 21, 2026 1 EN

KBC Securities

MaaT Pharma Randomises first patient in MaaT033 phase 2 trial in NSCLC

MaaT announced that the first patient has been randomised in the investigator sponsored multicenter phase 2 (IMMUNOLIFE) trial evaluating MaaT033 (microbiome therapy, oral capsule) in combination with cemiplimab (anti PD-1 antibody) in patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance to PD-1/PD-L1 blockade following antibiotic (ATB) exposure and who present ATB-induced gut dysbiosis. Primary results after 1-year follow-up post-treatment could be expected in late 2030, while an interim futility analysis is expected around 1H27, after the 81st randomised pa...

January 21, 2026 January 21, 2026 1 EN

KBC Securities

Morning Notes : ASM NA, MAAT FP

: ASM NA, MAAT FP

December 9, 2025 December 9, 2025 1 EN

Umicore Feedback FY25 results conference call

Below are the highlights from the conference call. We remind that FY25 adjusted EBITDA increased by 11% to 847m, slightly above the high end of the 790-840m guidance range (in line with KBCS estimate, 1% above consensus). The company did not give a precise guidance on FY26 although sounded cautious on developments in the EV industry. The strong metal price environment will partly be offset by lower hedging levels for 2026 and maintenance, while new longer term hedges generate additional earnings visibility at very attractive levels for a longer period of time. We maintain our Accumulate rating...

February 20, 2026 February 20, 2026 1 EN

Hilde Van Boxstael ... (+5)

Hilde Van Boxstael
Lynn Hautekeete
Mathijs Geerts Danau
Wim Hoste
Wim Lewi

Morning Notes : COFB BB, GLPG NA, UMI BB

: COFB BB, GLPG NA, UMI BB

February 20, 2026 February 20, 2026 1 EN

Lynn Hautekeete

Lynn Hautekeete

Cofinimmo FY25 results above expectations, guidance below

Cofinimmo reports recurring EPRA EPS +1,1% above our estimates and 4,0% above its guidance. The earnings beat is driven by higher like-for-like rental income at +2,9%. The EPRA EPS outlook of FY26 is below our estimates at € 6,35 vs € 6,39 KBCSe. The guided debt ratio at YE26 is 340 bps higher than our expectations at 44,0% due to only € 110,0m guided asset disposals and higher than expected investments at € 310,0m which will mainly impact FY27/28 rental income. In the medium term, the focus should be on refinancings. The average debt maturity is low at 3x which is related to the ongoing excha...

February 20, 2026 February 20, 2026 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MaaT Pharma - Doses first patient in phase 2b MaaT033 trial in allo-HSCT Doses first patient in phase 2b MaaT033 trial in allo-HSCT

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : OPTI BB, SOF BB, WDP BB, MAAT FP

MaaT Pharma Randomises first patient in MaaT033 phase 2 trial in NSCLC

Morning Notes : ASM NA, MAAT FP

Umicore Feedback FY25 results conference call

Morning Notes : COFB BB, GLPG NA, UMI BB

Cofinimmo FY25 results above expectations, guidance below

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe